ARTICLE | Clinical News
Veletri epoprostenol regulatory update
August 1, 2011 7:00 AM UTC
Actelion disclosed in its 1H11 earnings that it withdrew an application in France for Veletri epoprostenol to treat pulmonary arterial hypertension (PAH) in order to seek approval of a second generati...